Cargando…
Methylene Blue Delivery Mediated by Focused Ultrasound-Induced Blood–Brain Barrier Disruption Reduces Neural Damage and Amyloid-Beta Plaques by AQP-4 Upregulation
Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease worldwide, causing progressive cognitive decline, memory impairment, and neurological deficits. Methylene blue (MB), an antioxidant, has emerged as a potential drug for the treatment of AD owing to its cognitive improvement and...
Autores principales: | Choi, Hyo Jin, Han, Mun, Jung, Byeongjin, Hong, Yu-Ri, Shin, Seulgi, Lim, Sungsu, Lee, Eun-Hee, Kim, Yun Kyung, Park, Juyoung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776289/ https://www.ncbi.nlm.nih.gov/pubmed/36551947 http://dx.doi.org/10.3390/biomedicines10123191 |
Ejemplares similares
-
Methylene blue decreases brain mitochondrial ABAD and amyloid beta levels protecting mitochondrial functions in LPS-mouse model
por: Abdel-Kader, Reham M, et al.
Publicado: (2013) -
Methylene blue inhibits nucleation and elongation of SOD1 amyloid fibrils
por: Musteikyte, Greta, et al.
Publicado: (2020) -
Methylene blue relieves the development of osteoarthritis by upregulating lncRNA MEG3
por: Li, Xinyi, et al.
Publicado: (2018) -
Methylene Blue: Revisited
por: Ginimuge, Prashant R., et al.
Publicado: (2010) -
Methylene-Blue in Fevers
por: Frost, G. H.
Publicado: (1908)